Skip to main content
Fig. 2 | Arthritis Research & Therapy

Fig. 2

From: Comparative clinical efficacy and safety of the proposed biosimilar ABP 710 with infliximab reference product in patients with rheumatoid arthritis

Fig. 2

a Percentage of patients achieving ACR20, ACR50, and ACR70 by study week, ± 95% CI. ACR20, ACR50, and ACR70 is the 20, 50, and 70%, respectively, improvement from baseline in American College of Rheumatology core set measurements. b Mean ± 95% CI change from baseline DAS28-CRP by study week. c Percentage of Hybrid ACR improvement from baseline ± 95% CI. Hybrid ACR was calculated when all seven ACR components were non-missing. For post week 22, only re-randomized subjects were included

Back to article page